chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Employee was given the Moderna Vaccine and within 2 min employee started to feel chest discomfort, generalized tremors and light headed. The patient was given 2 doses of IM epinephrine and sent to the ER- 2:24 1st dose and 2:29 second dose. Arrived in the ER given diphenhydramine/famotidine/prednisone. RX given 0.3 IM for Epinephrine(Epi-pen)/Zyrtec and Famotidine and Predisone.  Seen in ER at 2:36 - patient states to ER MD that after epinephrine she feels much better. Evaluation  done and monitoring of vital sings in the ER . Doctor spent 38 minutes with patient and felt she was stable and discharged the patient home to self monitor and return to the ER at 4:28 PM. ER Doctor states no current signs of anaphylaxis, severe dehydration, live threatening emergency.  Advised to follow-up with PCP in 1-2 days. Employee was called and states she feels good and has no current symptoms other than a sore arm- 12/30/2020.
Arm is hot to the touch; Red band halfway between elbow and shoulder; Swelling; Pain; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (Arm is hot to the touch), ERYTHEMA (Red band halfway between elbow and shoulder), SWELLING (Swelling) and PAIN (Pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING HOT (Arm is hot to the touch), ERYTHEMA (Red band halfway between elbow and shoulder), SWELLING (Swelling) and PAIN (Pain). At the time of the report, FEELING HOT (Arm is hot to the touch) outcome was unknown and ERYTHEMA (Red band halfway between elbow and shoulder), SWELLING (Swelling) and PAIN (Pain) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications information was provided.  No treatment medications were reported.
Immediately post vax, the pt developed an injection site reaction described as cellulitis. The reporter indicated that 2 employees experienced this event, however, they are not presently identifiable.
flu-like symptoms; achiness; loss of appetite; tiredness; low grade fever of 100F and then went down to 99F; join pain; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), INFLUENZA LIKE ILLNESS (flu-like symptoms), PAIN (achiness), DECREASED APPETITE (loss of appetite) and FATIGUE (tiredness) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Idiopathic thrombocytopenic purpura (once a month she has blood drawn to check platelets.Her normal range is 30-70) and Shingles. Previously administered products included for an unreported indication: SHINGRIX. Concurrent medical conditions included Diabetic.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm). On 06-Mar-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu-like symptoms), PAIN (achiness), DECREASED APPETITE (loss of appetite), FATIGUE (tiredness), PYREXIA (low grade fever of 100F and then went down to 99F) and ARTHRALGIA (join pain). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Joint pain, at a dose of 2 at one time. On 10-Mar-2021, PAIN IN EXTREMITY (sore arm), INFLUENZA LIKE ILLNESS (flu-like symptoms), PAIN (achiness), DECREASED APPETITE (loss of appetite), FATIGUE (tiredness), PYREXIA (low grade fever of 100F and then went down to 99F) and ARTHRALGIA (join pain) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Mar-2021, Body temperature: 100 f (High) HIGH and 99 f (High) HIGH. On 05-Mar-2021, Platelet count: increased (High) platelet tripled, went up to 146. In March 2021, Platelet count: 146 (normal) NORMAL. On an unknown date, Platelet count:.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant information were not provided by the reporter.
This spontaneous report received from a consumer via other manufacturer (RA) concerned a 6 decade old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: ulcerative colitis. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: unknown and expiry: unknown) dose was not reported, 1 total, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Non-company suspect drugs included: adalimumab (Humira) (solution for injection in pre-filled pen, subcutaneous, batch number was not reported, expiry: unknown) dose, frequency, and therapy dates were not reported for moderate to severe ulcerative colitis.  Age at time of vaccination 52 years old. No concomitant medications were reported. On an unspecified date, the patient experienced diabetes, ache, colitis ulcerative aggravated/ flare up, and chills. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable; and action taken with adalimumab was not reported. The outcome of the chills, diabetes, ache and colitis ulcerative aggravated/flare up was not reported. This report was serious (Other Medically Important Condition). Sender's Comments: V0: 20220424725-COVID-19 VACCINE AD26.COV2.S-colitis ulcerative aggravated/flare up. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: MEDICAL HISTORY. Therefore, this event(s) is considered not related. 20220424725-COVID-19 VACCINE AD26.COV2.S- diabetes. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable.
Information has been received from a physician concerning a 4 month old female who was vaccinated with a first oral 2ml dose of Rotateq (human bovine) and a second oral 2 ml dose on 16 Nov 2006. Concomitant vaccinations administered on 16 Nov 2006 included "other shots". "About two hours later", on 16 Nov 2006, the patient severely vomited three times. The patient went to an urgent care clinic and did not need any intravenous fluids. The reported said the patient "seemed fine" when she saw her, but was "concerned about giving the third dose" of Rotateq (human bovine). It was reported that the patient recovered later on 16 Nov 2006. No product quality complaint was involved. No other information was provided. Additional information has been requested. This is in follow-up to report (s) previously submitted on 12/14/2006. Information has been received from a physician concerning a 17 week old female, with no medical history and no allergies, who was vaccinated with a first oral 2 ml dose of ROTATEQ and a second oral 2 ml dose (Lot# 654247/0600F) on 17-NOV-2006 (originally reported as 16-NOV-2006), at 3:00 pm. Concomitant vaccinations administered on 17-NOV-2006 included "other shots". There was no illness at the time of vaccination and no adverse events following prior vaccination. "About two hours later", on 17-NOV-2006 (originally reported as 16-NOV-2006), the patient severely vomited three times. The patient went to an urgent care clinic and did not need any intravenous fluids. The reporter said the patient "seemed fine" when she saw her, but was "concerned about giving the third dose" of ROTATEQ. It was reported that the patient recovered later on 18-NOV-2006 (originally reported as 17-NOV-2006). There were no laboratory or diagnostic tests performed. No product quality complaint was involved. No other information was provided. Follow-up information from a physician indicated that on 17-NOV-2006, at 3:30 PM, the patient vomited repeatedly and was seen in the emergency room.  The patient recovered on 18-NOV-2006.  Additional information is not expected.
Left upper arm pain occurring immediately after vaccine given. Now persisting > 3 weeks with severe radiating pain. U/S (-) for DVT. Tried NORCO, naproxen, LIDODERM patch, LYRICA, MEDROL with little relief.
When the shot went in, I was pleasantly surprised that it didn't hurt at all. Within a few minutes though, my arm became tense and then my face flushed and I got hot and sweaty.  I told the pharmacist that I wasn't feeling very well.  I would have fainted if he and my husband hadn't helped me lay down on the floor.  I laid there for 20 minutes with my head in my husband's lap, my feet propped up on a chair, the pharmacist making me drink water, and a blood pressure cuff on my arm - (my bp was normal or very slightly elevated).  After 20 minutes, I felt better and left.  I haven't had any symptoms since.  I have never had a reaction like this before.  I was not overly nervous.  I do have very mild hot flashes. This was significantly more than intense than a regular hot flash.
THERE WAS NO ADVERSE REACTION AFTER THE ADMINISTERED SHOT.  ONLY REPORTING BECAUSE THE VACCINE PFIZER FOR AGES 5-11 YEARS OLD WAS ADMINISTERED ON A 12 YEARS OLD AT OUR COVID VACCINATION SCHOOL OUTREACH CAMPAIGN.
This case was reported by a pharmacist via call center representative and described the occurrence of therapy non-responder in a child female patient who received Hepatitis B vaccine for prophylaxis. Co-suspect products included Hepatitis B vaccine for prophylaxis and Hepatitis B vaccine for prophylaxis. On an unknown date, the patient received the 1st dose of Hepatitis B vaccine, the 2nd dose of Hepatitis B vaccine and the 3rd dose of Hepatitis B vaccine. On an unknown date, unknown after receiving Hepatitis B vaccine, Hepatitis B vaccine and Hepatitis B vaccine, the patient experienced therapy non-responder. On an unknown date, the outcome of the therapy non-responder was unknown. It was unknown if the reporter considered the therapy non-responder to be related to Hepatitis B vaccine, Hepatitis B vaccine and Hepatitis B vaccine. Additional details were provided as follows: The patient was vaccinated as a child with the 3 doses of Hepatitis B series (unknown brand and unknown manufacturer). At the time of reporting, the patient was going to dental school and she got her titers drawn. The patient's Hepatitis B titers were less than 10 mIU per mL. The healthcare professional could not confirm that if the patient received ENGERIX B or another Hepatitis B vaccine as a child. The healthcare professional did not wish to be contacted by the patient safety. Lab Comments: On an unknown date, patient's antibody titer for hepatitis B was less than 10 miU per ml.
20 mins p/vax chills, n,v, & h/a w/in 60 mins; also soreness @ inject site rt deltoid (no erythema or pruritus) & myalgia rt elbow & rt wrist; inject site-4.5 cm induration x 2 days; also hot/cold & nasal congestion;
nuchal rigidity; migraine; photosensitivity; auditory sensitivity; arthralgia; lethargy chills/ rigors; nasal stuffiness; chest congestion; wet cough; This is a spontaneous report from a contactable physician. A 40-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number:EL1283), intramuscular on 08Jan2021 17:00 at a SINGLE DOSE for covid-19 immunisation. The patient's medical history was not reported. There were no concomitant medications. The patient had the first dose last 18Dec2020 (lot number=EJ1685). The patient experienced nuchal rigidity, migraine, photosensitivity, auditory sensitivity, arthralgia, lethargy chills, rigors, nasal stuffiness, chest congestion, wet cough on 09Jan2021 05:00. The outcome of the event nuchal rigidity was not recovered while other events were recovered with sequelae.
On 7/4/19, her right ear started to become warm and itchy. The next day on 7/5/19, she noticed it spreading to her scalp and turning pink. On 7/6/19, it was fire red on her outer ear and she began to see blisters which spread to her scalp and chin. She consulted with a dermatologist over the phone who thought it might be singles. She tried to apply an unknown ointment which did not help. She went to a walk in clinic on 7/15/19 to have somebody look at it, and they confirmed it was shingles and started her on a 5 day course of Valtrex.
Fever; Pain from her vaccine; Body aches; Now her symptoms are worse; Flu/cold symptoms; Sneezing; Cough; Feels like she is going to lose her voice; Feels like she is lacking oxygen; This is a spontaneous report from a contactable consumer (patient's brother). A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on 30Jan2021 as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. He is worried about his sister. She got her second dose of the vaccine on 30Jan2021. The issue is she started getting symptoms. The first day, she experienced pain from her vaccine. Next day fever. Then, she had body aches. Now her symptoms are worse. Now she has flu/cold like symptoms. She is sneezing and has a cough. She feels like she is going to lose her voice. She feels like she is lacking oxygen. He is wondering if this is normal for the vaccine. The outcome of the events was unknown.  Information on Lot/Batch has been requested.  Follow-up attempts are completed. No further information is expected.
Info has been received from a physician concerning a 4 year old male who in 2002, at age 1, was vaccinated with a dose of varicella virus vaccine live. In approximately April 2005 (reported as "very recently"), the pt developed 20 lesions on his trunk and in his mouth. Unspecified medical attention was sought. The pt had no fever and there were no other problems. Subsequently, the pt recovered one week after the lesions began. No product quality complaint was involved. Additional info has been requested.
dizziness started 9 days later.  Treatment-ER visit and discharged nonspecific. outcome: continues to work does not interfere with ADL. History of hypertension, BP elevated at ER visit.  Dizzy episodes last for 2-3 minutes.
Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Additional Details: 1 day after vaccines, pt had hives on both sides of trunk, pt took benadryl and symptoms went away
Nauseated time onset still going; Sore arm; Loss of appetite; Dry skin patch; Weight loss of 2 lbs; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had known allergies to collins and also had seasonal allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 14:15 the patient experienced nauseated time onset was still going two days later, sore arm, loss of appetite, dry skin patch and weight loss of 2 lbs. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of the events nauseated time onset was still going two days later, sore arm, loss of appetite, dry skin patch and weight loss were all not recovered at the time of this report.  No follow-up attempts are needed; information about lot\batch number cannot be obtained.
2AM chills, shaking, weakness;4AM hot burning, took liquids, fever;over next 48hr achiness, h/a, pain in head, couldn't bend over or move w/o head throbbing, fever, chills;12AUG96 swollen lt arm, weak, tired, red raised inj site;
Rapidly progressing hives.  Went to Children's National Medical Center ER and was given steroids, Ranitidine and Benadryl. No resp involvement.
I received the covid-19 vaccine and then afterwards contracted covid-19; I received the covid-19 vaccine and then afterwards contracted covid-19; This is a spontaneous report from a contactable nurse.  A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for covid-19 vaccine.  The patient medical history and concomitant medications were not reported.  The patient stated on an unspecified date, "I received the covid-19 vaccine and then afterwards contracted covid-19. I was told by my hospital that because of this I needed to defer the second dose for 90 days. Is this best practice? Or should I take the second dose in 3 weeks as scheduled?". The outcome of the events was unknown.    Information on the batch/lot number has been requested.; Sender's Comments: BNT162b2 provides protection against COVID-19 seven days after the second dose is administered. This case does not match this condition
Allergy in the form of a skin rash on my Ches, neck, belly and thighs. Appearance of shingles like sores in my groin area.
Redness, swelling from elbow to armpit that lasted about one week. Pt also complained of pain & itching. She used cold compresses, ibuprofen, & BENADRYL to treat symptoms. About 3 wks after vaccine some skin around injection site peeled off.
08/31/21 Janssen COIVD vaccine given. 01/06/22  Moderna COVID booster, vaccine given.  (.25ml) 02/11/22   Moderna COVID vaccine given. (0.5ml)  per providers insructions.
ended up testing positive for covid 19; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (ended up testing positive for covid 19) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (ended up testing positive for covid 19). At the time of the report, COVID-19 (ended up testing positive for covid 19) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 22-OCT-2015, the patient was vaccinated with improperly stored RECOMBIVAX HB (exposed to the following temperatures and cumulative time frames colder than 36F: In September of 2015, the coldest temperature was 34F for 346.7 hours (over 14 days); In October of 2015, the coldest temperature was 34F for 492.6 hours for a total of 839.3 hours (35 days); In November of 2015, the coldest temperature was 34F for 192 hours, for a total of 1,031.3 hours (43 days)) with lot number: L010595, expiry date: 12-NOV-2016 (dose and strength unspecified). No concomitant medications were reported. No adverse effects were reported. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of the several reports from the same reporter. Additional information has been requested.
Got flu vaccine during a follow-up visit in the office. Was at appointment with dad. Mom called later in the evening and reported patient had gotten flu vaccine in October during a visit that she attended with him. October vaccine not documented so unsure of lot number.
PATIENT REPORTS GETTING SHINGLES FROM THE VACCINE, HAD FIRST DOSE 6/12 WITH NO REACTION. SEEN BY EMERGENCY DEPARTMENT AND GIVEN ANTIBIOTIC AND ANTIBACTERIAL OINTMENT FOR SORES.
Several minutes after receiving immunizations (At approx 3 PM) child developed a single hive 10mm in size adjacent to MMRV administration site.  No other adverse events or other hives.  Color was good. No respiratory problems.  Child playing, walking and drinking bottle.  Hrt rate 132.  Observed child for 50 minutes and no changes in status.  Hive fading.  ER was notified and child transported by parents to local ER at about 3:52 PM.  Per phone call to mom on 9/9 child was ordered benadryl po and tylenol/motrin alternating.  Other than mild fever child not experiencing any other problems.
Fever; Chills; Achy; The patient received third/booster dose of BNT162b2; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old male patient received the third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 07Nov2021 (at the age of 31-years-old), as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received influenza vaccine (MANUFACTURER UNKNOWN) for immunisation on an unknown date in 2021. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EI3248) via an unspecified route of administration on 03Mar2021 (at the age of 30-years-old) and also second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on 23Mar2021 (at the age of 30-years-old); as a single dose for COVID-19 immunisation. On 08Nov2021, the patient experienced fever, chills and felt achy. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills and achy were resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
My sense of taste and smell has switched. Food and smells I love now are horrible and vice versa.